Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma

The key factors leading to transformed follicular lymphoma (t-FL) include the aberrations of epigenetic modifiers as early and driving events, especially mutations in the gene encoding for histone acetyltransferase. Therefore, reversal of this phenomenon by histone deacetylase (HDAC) inhibitors is e...

Full description

Bibliographic Details
Main Authors: Mengya Zhong, Jinshui Tan, Guangchao Pan, Yuelong Jiang, Hui Zhou, Qian Lai, Qinwei Chen, Liyuan Fan, Manman Deng, Bing Xu, Jie Zha
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-12-01
Series:Frontiers in Oncology
Subjects:
transformed-follicular lymphoma (t-FL)
chidamide
HDAC
PI3K/AKT signaling
epigenetic antitumor therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.780118/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.780118/full

Similar Items